In the realms of biotechnology and immunotherapy, antibodies have long stood as formidable weapons against various diseases, notably cancer and autoimmune conditions. Conventionally, immunoglobulin G (IgG) antibodies have dominated this arena. However, recent strides in non-IgG antibody engineering herald a transformative era, promising more potent and adaptable therapies.   While IgG...